Cargando…

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma

Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalela, Roberto, Bellosillo, Beatriz, Curull, Víctor, Longarón, Raquel, Pascual-Guardia, Sergi, Badenes-Bonet, Diana, Arriola, Edurne, Sánchez-Font, Albert, Pijuan, Lara, Gea, Joaquim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518197/
https://www.ncbi.nlm.nih.gov/pubmed/30999636
http://dx.doi.org/10.3390/jcm8040529
_version_ 1783418411206836224
author Chalela, Roberto
Bellosillo, Beatriz
Curull, Víctor
Longarón, Raquel
Pascual-Guardia, Sergi
Badenes-Bonet, Diana
Arriola, Edurne
Sánchez-Font, Albert
Pijuan, Lara
Gea, Joaquim
author_facet Chalela, Roberto
Bellosillo, Beatriz
Curull, Víctor
Longarón, Raquel
Pascual-Guardia, Sergi
Badenes-Bonet, Diana
Arriola, Edurne
Sánchez-Font, Albert
Pijuan, Lara
Gea, Joaquim
author_sort Chalela, Roberto
collection PubMed
description Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications.
format Online
Article
Text
id pubmed-6518197
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65181972019-05-31 EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma Chalela, Roberto Bellosillo, Beatriz Curull, Víctor Longarón, Raquel Pascual-Guardia, Sergi Badenes-Bonet, Diana Arriola, Edurne Sánchez-Font, Albert Pijuan, Lara Gea, Joaquim J Clin Med Article Tumor recurrence is frequent and survival rates remain extremely low in lung adenocarcinoma (ADC). We hypothesize that carcinogenic factors will promote loco-regional modifications not only in the future tumor, but throughout the exposed lung. Objective: To analyze whether the most prevalent mutations observed in ADC can also be observed in the non-neoplastic lung tissue, as well as the short-term prognosis implications of this finding. Methods: Non-tumoral lung parenchyma specimens obtained during surgery from 47 patients with EGFR and/or KRAS abnormalities in their ADC tumors underwent similar genomic testing. Short-term outcomes were also recorded. Results: The same mutations were present in the tumor and the histologically normal tissue in 21.3% of patients (SM group). Although local recurrences were similar in both groups, distant metastases were more frequent in the former (60 vs. 5.4%, p < 0.001). Moreover, SM patients showed lower time-to-progression (8.5 vs. 11.7 months, p < 0.001) and disease-free survival (8.5 vs. 11.2 months, p < 0.001). COX regression showed a higher risk of progression or death (DFS) in the SM group (HR 5.94, p < 0.01]. Similar results were observed when adjusting for potential confounding variables. Conclusions: These results confirm that genetic changes are present in the apparently normal lung in many ADC patients, and this finding has prognostic implications. MDPI 2019-04-17 /pmc/articles/PMC6518197/ /pubmed/30999636 http://dx.doi.org/10.3390/jcm8040529 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chalela, Roberto
Bellosillo, Beatriz
Curull, Víctor
Longarón, Raquel
Pascual-Guardia, Sergi
Badenes-Bonet, Diana
Arriola, Edurne
Sánchez-Font, Albert
Pijuan, Lara
Gea, Joaquim
EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title_full EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title_fullStr EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title_full_unstemmed EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title_short EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
title_sort egfr and kras mutations in the non-tumoral lung. prognosis in patients with adenocarcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518197/
https://www.ncbi.nlm.nih.gov/pubmed/30999636
http://dx.doi.org/10.3390/jcm8040529
work_keys_str_mv AT chalelaroberto egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT bellosillobeatriz egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT curullvictor egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT longaronraquel egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT pascualguardiasergi egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT badenesbonetdiana egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT arriolaedurne egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT sanchezfontalbert egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT pijuanlara egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma
AT geajoaquim egfrandkrasmutationsinthenontumorallungprognosisinpatientswithadenocarcinoma